Barchart.com
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
alerts false
Stocks | Futures | Watchlist | News | More
 
Advanced search
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
314.19 +5.40 (+1.75%) 13:46 ET [NASDAQ]
311.90 x 100 314.31 x 1
Realtime by (Cboe BZX)
311.90 x 100 314.31 x 1
Realtime 306.90 -1.89 (-0.61%) 09:03 ET
News & Headlines for Thu, Apr 24th, 2025
Notes
Alerts
Watch
    Add or delete the symbol from one or more Watchlists.
  • Create New Watchlist
    This name already in use.
Help
Go To:
Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 GlobeNewswire - Fri Apr 18, 7:00AM CDT

MDGL : 314.19 (+1.75%)
Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. to Become Senior Scientific and Medical Advisor; David Soergel, M.D., Appointed Chief Medical Officer GlobeNewswire - Wed Apr 16, 6:00AM CDT

MDGL : 314.19 (+1.75%)
Madrigal Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors GlobeNewswire - Tue Mar 11, 7:00AM CDT

MDGL : 314.19 (+1.75%)
Why Madrigal Pharmaceuticals Stock Is Soaring Today Motley Fool - Wed Feb 26, 10:27AM CST

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain came after the small biopharmaceutical company announced its fourth-quarter and...

MDGL : 314.19 (+1.75%)
Madrigal: Q4 Earnings Snapshot AP - Wed Feb 26, 6:21AM CST

Madrigal: Q4 Earnings Snapshot

MDGL : 314.19 (+1.75%)
Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffraâ„¢ (resmetirom) in Patients with Compensated MASH Cirrhosis GlobeNewswire - Wed Feb 26, 6:00AM CST

MDGL : 314.19 (+1.75%)
Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffraâ„¢ (resmetirom) in Patients with Compensated MASH Cirrhosis GlobeNewswire - Wed Feb 26, 5:30AM CST

MDGL : 314.19 (+1.75%)
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference GlobeNewswire - Fri Feb 21, 7:00AM CST

MDGL : 314.19 (+1.75%)
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025 GlobeNewswire - Wed Feb 12, 7:00AM CST

MDGL : 314.19 (+1.75%)
Why Madrigal Pharmaceuticals Stock Was Plummeting This Week Motley Fool - Fri Jan 17, 7:28AM CST

An estimates-beating set of preliminary financial numbers and two bullish analyst updates weren't enough to lift Madrigal Pharmaceuticals (NASDAQ: MDGL) stock out of the doldrums over the past few trading...

MDGL : 314.19 (+1.75%)
GS : 543.70 (+2.72%)

Barchart Exclusives

Unusual Options Activity: Toast Makes a Tasty LEAP for Conservative Investors Barchart - 19 minutes ago
Toast had one unusually active option on Wednesday among the 1,053 puts and calls, but it’s all the conservative investor needs to make a bet on the fast-growing restaurant software business. Here’s why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective
Wed, Apr 30, 2025 5:00 PM UTC
Reserve Your Spot